

The effect of food on the proportion of chondroitin sulfate that enters the blood after Condrosulf® tablets are taken in healthy male and female volunteers

| | | |
|--|---|---|
| Submission date 30/05/2022 | Recruitment status No longer recruiting | <input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol |
| Registration date 03/06/2022 | Overall study status Completed | <input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results |
| Last Edited 01/02/2023 | Condition category Other | <input type="checkbox"/> Individual participant data |

Plain English summary of protocol

Background and study aims

Chondroitin sulfate is a substance found naturally in the human body. It is taken as a supplement for joint problems. This study aimed to investigate the bioavailability (how much of a substance enters the bloodstream) and pharmacokinetics (the way a substance medicine moves inside the body) of chondroitin sulfate after healthy volunteers took Condrosulf® tablets containing chondroitin sulfate and also to investigate whether the tablets had any side effects.

Who can participate?

Healthy men and women aged 30-65 years inclusive

What does the study involve?

Participants received a single 1600 mg dose of chondroitin sulfate tablets on two separate days, once after they had eaten no breakfast and once after they had eaten a substantial breakfast. Blood was taken at intervals before and after the tablets were taken.

What are the possible benefits and risks of participating?

Chondroitin sulfate is widely used and is considered safe. No potential risks were foreseen for the subjects enrolled in the present study. In previous clinical studies, the most common side effects involved the gut, i.e. indigestion and abdominal pain, and the nervous system, i.e. headache (which occurred in less than 10% of patients). Nausea, constipation, dizziness and skin disorders (rashes) occurred in less than 1% of patients. However, as with all products, the appearance of known or not yet known allergic reactions or side effects couldn't be ruled out. No potential benefits were foreseen to volunteers participating to the current study with the exception of the medical tests that were performed during it.

Where is the study run from?

CROSS Research S.A. Phase I Unit Clinical Centre (Switzerland)

When is the study starting and how long is it expected to run for?
February 2020 to June 2021

Who is funding the study?
IBSA Institut Biochimique SA, Switzerland

Who is the main contact?
Marta Bignamini
sd@ibsa.ch

Contact information

Type(s)

Public

Contact name

Mrs Marta Bignamini

Contact details

IBSA Institut Biochimique S.A.
via del Piano 29, PO Box 266
Pambio-Noranco
Switzerland
6915
+41.58.360.10.00
sd@ibsa.ch

Type(s)

Scientific

Contact name

Mrs Marta Bignamini

Contact details

IBSA Institut Biochimique S.A.
via del Piano 29, PO Box 266
Pambio-Noranco
Switzerland
6915
+41.58.360.10.00
sd@ibsa.ch

Type(s)

Principal investigator

Contact name

Dr Milko Radicioni

ORCID ID

<https://orcid.org/0000-0002-3940-8375>

Contact details

CROSS Research S.A., Phase I Unit
Via F.A. Giorgioli 14
Arzo
Switzerland
6864
+41.91.64.04.450
clinic@croalliance.com

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

Protocol serial number

20CH-Ct04, CRO-PK-21-351

Study information

Scientific Title

Food effect study of Condrosulf® chondroitin sulfate tablets in healthy male and female volunteers

Study objectives

The objective of the study was to investigate the effect of food on the bioavailability of total chondroitin sulfate* after single dose of Condrosulf®, administered under fed and fasting conditions to healthy male and female subjects.

*Note: chondroitin sulfate was calculated as the sum of Δ Di-4S, Δ Di-0S, Δ Di-6S disaccharides

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 13/04/2021, Canton Ticino Ethics Committee (c/o Ufficio di sanità, Via Orico 5, 6501 Bellinzona, Switzerland; +41(0)91 814 30 57; michaela.gutacker@ti.ch), ref: 2021-00716 / CE 3854

Study design

Single-dose, single-center, open-label, randomized, two-way, cross-over, food effect study

Primary study design

Interventional

Study type(s)

Other

Health condition(s) or problem(s) studied

Food effect study in healthy volunteers

Interventions

Investigational product: Condrosulf®, chondroitin sulfate 800 mg tablets, IBSA Institut Biochimique SA, Switzerland.

A single 1600 mg dose of chondroitin sulfate tablet was administered in each of two consecutive study periods, under fed and fasting conditions, according to a two-way cross-over randomized design. The investigational product was administered as two 800 mg tablets to be taken consecutively with 240 ml of still mineral water. A wash-out interval of at least 7 days elapsed between the consecutive administrations. Subjects allocated to treatment under fed conditions were provided with a standardized high-fat high-caloric breakfast 30 min pre-dose. They had to completely eat their breakfast within 30 min and before investigational product administration. Subjects allocated to treatment under fasting conditions didn't receive any food before administration.

Intervention Type

Drug

Phase

Phase I

Drug/device/biological/vaccine name(s)

Condrosulf® (chondroitin sulfate 800 mg tablets)

Primary outcome(s)

Chondroitin sulfate C_{max}, AUC_{0-t} and AUC_{0-∞} calculated from levels measured using a fully validated analytical LC-MS/MS method in blood collected on Day -2 and Day -1 at 8:00 ±1 h, 13:00 ±1 h, 20:00 ±1 h and on Days 1, 2 and 3 at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 36 and 48 h post-dose

Key secondary outcome(s)

1. Chondroitin sulfate t_{max}, t_{1/2}, λ_z, Cl/F and V_d/F calculated from levels measured using a fully validated analytical LC-MS/MS method in blood collected on Day -2 and Day -1 at 8:00 ±1 h, 13:00 ±1 h, 20:00 ±1 h and on Days 1, 2 and 3 at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 36 and 48 h post-dose
2. ΔDi-4S, ΔDi-0S, ΔDi-6S disaccharides bioavailability calculated from levels measured using a fully validated analytical LC-MS/MS method in blood collected on Day -2 and Day -1 at 8:00 ±1 h, 13:00 ±1 h, 20:00 ±1 h and on Days 1, 2 and 3 at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 36 and 48 h post-dose
3. Safety and tolerability assessed using treatment-emergent adverse events recorded throughout the study duration
4. Blood pressure measured by the Investigator or his deputy after 5 min at rest (in sitting position) using a manual sphygmomanometer at the screening visit, at Day 1 of each period pre-dose and 3 h post-dose, Day 2 of each period 24 h post-dose, Day 3 of each period 48 h post-dose and at the early termination visit (if applicable)
5. Heart rate measured by the Investigator or his deputy after 5 min at rest (in sitting position) using a manual sphygmomanometer at the screening visit, at Day 1 of each period pre-dose and 3 h post-dose, Day 2 of each period 24 h post-dose, Day 3 of each period 48 h post-dose and at the early termination visit (if applicable)
6. Electrocardiographic evaluation and ECG parameters measured using 12-lead ECG performed in supine position at screening and final visit/early termination visit
7. Body weight measured using a professional personal floor scale at screening and final visit /early termination visit
8. Height measured using a stadiometer at screening
9. A standard panel of haematological and urinary parameters measured using laboratory testing on blood and urine samples collected at screening and final visit/early termination visit

Completion date

14/06/2021

Eligibility**Key inclusion criteria**

1. Signed written informed consent before inclusion in the study
2. Men and women aged 30-65 years inclusive
3. Body mass index (BMI) of 18.5-30 kg/m² inclusive
4. Systolic blood pressure 100-139 mmHg, diastolic blood pressure 50-89 mmHg, heart rate 50-90 bpm, measured after 5 min at rest in the sitting position
5. Ability to comprehend the full nature and purpose of the study, including possible risks and side effects; ability to co-operate with the Investigator and to comply with the requirements of the entire study
6. Contraception and fertility (women only): women of child-bearing potential must be using at least one of the following reliable methods of contraception:
 - 6.1. Hormonal oral, implantable, transdermal, or injectable contraceptives for at least 2 months before the screening visit
 - 6.2. A non-hormonal intrauterine device or female condom with spermicide or contraceptive sponge with spermicide or diaphragm with spermicide or cervical cap with spermicide for at least 2 months before the screening visit
 - 6.3. A male sexual partner who agrees to use a male condom with spermicide
 - 6.4. A sterile sexual partner
7. Women of non-child-bearing potential or in post-menopausal status for at least 1 year will be admitted. For all women, pregnancy test result must be negative at screening.

Participant type(s)

Healthy volunteer

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

30 years

Upper age limit

65 years

Sex

All

Total final enrolment

17

Key exclusion criteria

1. Electrocardiogram (ECG 12-leads, supine position) shows clinically significant abnormalities
2. Clinically significant abnormal physical findings which could interfere with the objectives of

the study

3. Clinically significant abnormal laboratory values indicative of physical illness
4. Ascertained or presumptive hypersensitivity to the active principle (chondroitin sulfate) and /or formulations' ingredients or history of anaphylaxis to drugs or allergic reactions in general, which the Investigator considers may affect the outcome of the study
5. Significant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, hematological, endocrine or neurological diseases that may interfere with the aim of the study
6. Medications, including over-the-counter medications, herbal remedies and food supplements containing chondroitin sulfate for 2 weeks before the start of the study. Hormonal contraceptives for females will be allowed.
7. Participation in the evaluation of any investigational product for 3 months before this study. The 3-month interval is calculated as the time between the first calendar day of the month that follows the last visit of the previous study and the first day of the present study.
8. Blood donations for 3 months before this study
9. History of drug, alcohol (>1 drink/day for females and >2 drinks/day for males, defined according to the USDA Dietary Guidelines 2020-2025), caffeine (>5 cups coffee/tea/day) or tobacco abuse (10 cigarettes/day)
10. Positive result in drug test at screening or Day -3
11. Positive alcohol breath test at Day -3
12. Abnormal diets (<1600 or >3500 kcal/day) or substantial changes in eating habits in the 4 weeks before this study or vegetarians;
13. Pregnancy (women only): positive or missing pregnancy test at screening or Day -3 or pregnant or lactating women

Date of first enrolment

25/05/2021

Date of final enrolment

29/05/2021

Locations

Countries of recruitment

Italy

Switzerland

Study participating centre

CROSS Research S.A., Phase I Unit

Via F.A. Giorgioli, 14

Arzo

Switzerland

6864

Sponsor information

Organisation

IBSA Institut Biochimique (Switzerland)

ROR

<https://ror.org/051tj3a26>

Funder(s)

Funder type

Industry

Funder Name

IBSA Institut Biochimique S.A.

Results and Publications

Individual participant data (IPD) sharing plan

The data sharing plans for the current study are unknown and will be made available at a later date.

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|-------------------------------|--------------|--------------|------------|----------------|-----------------|
| Basic results | version 2022 | 22/11/2022 | 25/11/2022 | No | No |